FDA approves Actelion's Uptravi

FDA approved Uptravi selexipag from Actelion Ltd. (SIX:ATLN) to treat pulmonary arterial hypertension (PAH). Actelion plans to launch the long-acting prostacyclin (IP) receptor ( PGI2; PTGIR) agonist in early January 2016.

The company did not respond to inquiries regarding Uptravi's price. The therapy has Orphan Drug designation from FDA. ...